{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:14:10Z","timestamp":1791216850938,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2013,8,6]]},"DOI":"10.1038\/bjc.2013.360","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T16:01:07Z","timestamp":1373385667000},"page":"686-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["RETRACTED ARTICLE: Angiogenic and signalling proteins\n              correlate with sensitivity to sequential treatment in renal cell cancer"],"prefix":"10.1038","volume":"109","author":[{"given":"R","family":"Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"BFbjc2013360_CR1","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-07-4905","volume":"14","author":"R Bianco","year":"2008","unstructured":"Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S,\n                  Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F,\n                  Tortora G (2008) Vascular endothelial growth factor receptor-1 contributes to\n                  resistance to anti-epidermal growth factor receptor drugs in human cancer cells.\n                    Clin Cancer Res\n                  14: 5069\u20135080.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013360_CR2","doi-asserted-by":"publisher","first-page":"e15039","DOI":"10.1200\/jco.2010.28.15_suppl.e15039","volume":"28","author":"GA Bjarnason","year":"2010","unstructured":"Bjarnason GA, Hudson JM, Bailey C, Lee CR, Williams R, Lloyd BA,\n                  Kerbel R, Stanisz GJ, Atri M, Burns P (2010) Microbubble ultrasound compared to\n                  dynamic contrast MRI and CT for the assessment of vascular response to sunitinib\n                  in renal cell carcinoma. J Clin Oncol\n                  28(ASCO Meeting suppl): abstract\n                  e15039.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013360_CR3","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-11-1185","volume":"17","author":"C Carbone","year":"2011","unstructured":"Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ,\n                  Abbruzzese JL, Melisi D (2011) Anti-VEGF treatment-resistant pancreatic cancers\n                  secrete proinflammatory factors that contribute to malignant progression by\n                  inducing an EMT cell phenotype. Clin Cancer Res\n                  17: 5822\u20135832.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013360_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug\n                  resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage\n                  pancreatic islet tumors. Cancer Cell\n                  8: 299\u2013309.","journal-title":"Cancer Cell"},{"key":"BFbjc2013360_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.110.175786","volume":"337","author":"KF Chen","year":"2011","unstructured":"Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL (2011)\n                  Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates\n                  acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther\n                  337: 155\u2013161.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFbjc2013360_CR6","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","volume":"16","author":"DC Cho","year":"2010","unstructured":"Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB,\n                  Signoretti S, Mier JW (2010) The efficacy of the novel dual PI3-kinase\/mTOR\n                  inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res\n                  16: 3628\u20133638.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013360_CR7","doi-asserted-by":"publisher","first-page":"12468","DOI":"10.1073\/pnas.0705226104","volume":"104","author":"V Damiano","year":"2007","unstructured":"Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G,\n                  Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S,\n                  Ciardiello F, Tortora G (2007) TLR9 agonist acts by different mechanisms\n                  synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer\n                  xenografts. Proc Natl Acad Sci USA\n                  104: 12468\u201312473.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc2013360_CR8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/bjc.2013.153","volume":"108","author":"V Damiano","year":"2013","unstructured":"Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R,\n                  Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora\n                  G (2013) Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell\n                  carcinoma by interfering with tumour growth and angiogenesis. Br J Cancer\n                  108: 1616\u20131623.","journal-title":"Br J Cancer"},{"key":"BFbjc2013360_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"J Dancey","year":"2010","unstructured":"Dancey J (2010) mTOR signaling and drug development in cancer.\n                    Nat Rev Clin Oncol\n                  7: 209\u2013219.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc2013360_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.eururo.2010.09.008","volume":"58","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega\n                  C, Aieta M, D\u2019Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C,\n                  Aglietta M, De Placido S, Mirone V (2010) Third-line sorafenib after sequential\n                  therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.\n                    Eur Urol\n                  58: 906\u2013911.","journal-title":"Eur Urol"},{"key":"BFbjc2013360_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M,\n                  Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M,\n                  Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM TARGET Study Group (2007a)\n                  Sorafenib in advanced clear-cell renal-cell carcinoma. N\n                    Engl J Med\n                  356: 125\u2013134.","journal-title":"N Engl J Med"},{"key":"BFbjc2013360_CR12","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S,\n                  Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO,\n                  Bodrogi I, Jagiello-Gruszfeld A, Moore N AVOREN Trial investigators (2007b)\n                  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell\n                  carcinoma: a randomised, double-blind phase III trial. Lancet\n                  370: 2103\u20132111.","journal-title":"Lancet"},{"key":"BFbjc2013360_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2012.59","volume":"9","author":"B Escudier","year":"2012","unstructured":"Escudier B, Szczylik C, Porta C, Gore M (2012) Treatment selection\n                  in metastatic renal cell carcinoma: expert consensus. Nat\n                    Rev Clin Oncol\n                  9: 327\u2013337.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc2013360_CR14","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/13543784.17.11.1619","volume":"17","author":"S Faivre","year":"2008","unstructured":"Faivre S, Raymond E (2008) Mechanism of action of rapalogues: the\n                  antiangiogenic hypothesis. Expert Opin Investig\n                    Drugs\n                  17: 1619\u20131621.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbjc2013360_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1586\/era.12.149","volume":"12","author":"A Felici","year":"2012","unstructured":"Felici A, Bria E, Tortora G, Cognetti F, Milella M (2012)\n                  Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.\n                    Expert Rev Anticancer Ther\n                  12: 1545\u20131557.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFbjc2013360_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/bjc.2011.389","volume":"105","author":"V Gr\u00fcnwald","year":"2011","unstructured":"Gr\u00fcnwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S (2011)\n                  Treatment of everolimus-resistant metastatic renal cell carcinoma with\n                  VEGF-targeted therapies. Br J Cancer\n                  105: 1635\u20131639.","journal-title":"Br J Cancer"},{"key":"BFbjc2013360_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R,\n                  Futreal PA, Furge KA, Teh BT (2010) Interleukin-8 mediates resistance to\n                  antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res\n                  70: 1063\u20131071.","journal-title":"Cancer Res"},{"key":"BFbjc2013360_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1756-9966-30-88","volume":"30","author":"B Huang","year":"2011","unstructured":"Huang B, Cao K, Li X, Guo S, Mao X, Wang Z, Zhuang J, Pan J, Mo C,\n                  Chen J, Qiu S (2011) The expression and role of protein kinase C (PKC) epsilon in\n                  clear cell renal cell carcinoma. J Exp Clin Cancer\n                    Res\n                  30: 88.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFbjc2013360_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A,\n                  Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V,\n                  Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer\n                  RJ Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced\n                  renal-cell carcinoma. N Engl J Med\n                  356: 2271\u20132281.","journal-title":"N Engl J Med"},{"key":"BFbjc2013360_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1756-9966-31-22","volume":"31","author":"SQ Ji","year":"2012","unstructured":"Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ (2012) Knockdown of the\n                  nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal\n                  cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer\n                    Res\n                  31: 22.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFbjc2013360_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1541-7786.MCR-12-0117","volume":"10","author":"E Jonasch","year":"2012","unstructured":"Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J,\n                  Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB,\n                  Walker CL, Rathmell WK (2012) State of the science: an update on renal cell\n                  carcinoma. Mol Cancer Res\n                  10: 859\u2013880.","journal-title":"Mol Cancer Res"},{"key":"BFbjc2013360_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-9-161","volume":"9","author":"E Juengel","year":"2009","unstructured":"Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L,\n                  Jonas D, Blaheta RA (2009) Combining the receptor tyrosine kinase inhibitor AEE788\n                  and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits\n                  adhesion and growth of renal cell carcinoma cells. BMC\n                    Cancer\n                  9: 161.","journal-title":"BMC Cancer"},{"key":"BFbjc2013360_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.eururo.2010.11.043","volume":"59","author":"JA Karam","year":"2011","unstructured":"Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp\n                  SH, Wood CG (2011) Development and characterization of clinically relevant tumor\n                  models from patients with renal cell carcinoma. Eur\n                    Urol\n                  59: 619\u2013628.","journal-title":"Eur Urol"},{"key":"BFbjc2013360_CR24","first-page":"3161","volume":"32","author":"MJ Kim","year":"2012","unstructured":"Kim MJ, Kim DE, Jeong IG, Choi J, Jang S, Lee JH, Ro S, Hwang JJ,\n                  Kim CS (2012) HDAC inhibitors synergize antiproliferative effect of sorafenib in\n                  renal cell carcinoma cells. Anticancer Res\n                  32: 3161\u20133168.","journal-title":"Anticancer Res"},{"key":"BFbjc2013360_CR25","first-page":"2399","volume":"32","author":"J Larkin","year":"2012","unstructured":"Larkin J, Esser N, Calvo E, Tsuchihashi Z, Fiedler U, Graeser R,\n                  Kim D (2012) Efficacy of sequential treatment with sunitinib-everolimus in an\n                  orthotopic mouse model of renal cell carcinoma. Anticancer\n                    Res\n                  32: 2399\u20132406.","journal-title":"Anticancer Res"},{"key":"BFbjc2013360_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1074\/jbc.M508199200","volume":"281","author":"WC Liang","year":"2006","unstructured":"Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik\n                  AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth\n                  factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor\n                  xenografts and measure the contribution of stromal VEGF. J\n                    Biol Chem\n                  281: 951\u2013961.","journal-title":"J Biol Chem"},{"key":"BFbjc2013360_CR27","first-page":"33","volume":"1","author":"L Lipworth","year":"2009","unstructured":"Lipworth L, Tarone RE, Lund L, McLaughlin JK (2009) Epidemiologic\n                  characteristics and risk factors for renal cell cancer. Clin Epidemiol\n                  1: 33\u201343.","journal-title":"Clin Epidemiol"},{"key":"BFbjc2013360_CR28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1158\/1535-7163.MCT-09-0119","volume":"8","author":"JY Liu","year":"2009","unstructured":"Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH (2009)\n                  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to\n                  its effect profile in vivo. Mol Cancer Ther\n                  8: 2193\u20132203.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2013360_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe\n                  O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA\n                  (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.\n                    N Engl J Med\n                  356: 115\u2013124.","journal-title":"N Engl J Med"},{"key":"BFbjc2013360_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S,\n                  Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A,\n                  Lebwohl D, Ravaud A RECORD-1 Study Group (2008) Efficacy of everolimus in advanced\n                  renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III\n                  trial. Lancet\n                  372: 449\u2013456.","journal-title":"Lancet"},{"key":"BFbjc2013360_CR31","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ctrv.2012.01.003","volume":"38","author":"A Ravaud","year":"2012","unstructured":"Ravaud A, Gross-Goupil M (2012) Overcoming resistance to tyrosine\n                  kinase inhibitors in renal cell carcinoma. Cancer Treat\n                    Rev\n                  38: 996\u20131003.","journal-title":"Cancer Treat Rev"},{"key":"BFbjc2013360_CR32","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","volume":"10","author":"BI Rini","year":"2009","unstructured":"Rini BI, Atkins MB (2009) Resistance to targeted therapy in\n                  renal-cell carcinoma. Lancet Oncol\n                  10: 992\u20131000.","journal-title":"Lancet Oncol"},{"key":"BFbjc2013360_CR33","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2012","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE,\n                  Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D,\n                  Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2012)\n                  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell\n                  carcinoma (AXIS): a randomised phase 3 trial. Lancet\n                  378: 1931\u20131939.","journal-title":"Lancet"},{"key":"BFbjc2013360_CR34","doi-asserted-by":"publisher","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-10-3376","volume":"17","author":"R Rosa","year":"2011","unstructured":"Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T,\n                  Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G (2011) Toll-like\n                  receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and\n                  pancreatic cancers. Clin Cancer Res\n                  17: 6531\u20136541.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2013360_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgl143","volume":"28","author":"T Shinojima","year":"2007","unstructured":"Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M\n                  (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression\n                  maintain vascular endothelial growth factor expression through HIF-2alpha.\n                    Carcinogenesis\n                  28: 529\u2013536.","journal-title":"Carcinogenesis"},{"key":"BFbjc2013360_CR36","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/bjc.2012.399","volume":"107","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Choueiri TK (2012) Biomarkers: the next therapeutic\n                  hurdle in metastatic renal cell carcinoma. Br J\n                    Cancer\n                  107: 1009\u20131016.","journal-title":"Br J Cancer"},{"key":"BFbjc2013360_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J,\n                  Barrios CH, Salman P, Gladkov OA, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L,\n                  Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic\n                  renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol\n                  28: 1061\u20131068.","journal-title":"J Clin Oncol"},{"key":"BFbjc2013360_CR38","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.juro.2010.07.033","volume":"184","author":"A Takeuchi","year":"2010","unstructured":"Takeuchi A, Eto M, Tatsugami K, Yamada H, Oki T, Kiyoshima K,\n                  Yoshikai Y, Naito S (2010) Mechanism of synergistic antitumor effect of sorafenib\n                  and interferon-\u03b1 on treatment of renal cell carcinoma. J\n                    Urol\n                  184: 2549\u20132556.","journal-title":"J Urol"},{"key":"BFbjc2013360_CR39","doi-asserted-by":"publisher","first-page":"34495","DOI":"10.1074\/jbc.C800170200","volume":"283","author":"A Toschi","year":"2008","unstructured":"Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential\n                  dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.\n                    J Biol Chem\n                  283: 34495\u201334499.","journal-title":"J Biol Chem"},{"key":"BFbjc2013360_CR40","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1093\/emboj\/cdg408","volume":"22","author":"A Viloria-Petit","year":"2003","unstructured":"Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May\n                  L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J (2003) Contrasting effects of VEGF\n                  gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.\n                    EMBO J\n                  22: 4091\u20134102.","journal-title":"EMBO J"},{"key":"BFbjc2013360_CR41","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","volume":"29","author":"CF Xu","year":"2011","unstructured":"Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, De\n                  Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon\n                  LR, Mooser VE, Pandite LN (2011) Pazopanib efficacy in renal cell carcinoma:\n                  evidence for predictive genetic markers in angiogenesis-related and\n                  exposure-related genes. J Clin Oncol\n                  29: 2557\u20132564.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1038\/s41416-025-03210-2","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"record-id":"67299"},{"DOI":"10.1038\/s41416-025-03210-2","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bjc2013360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013360","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2013360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:28:57Z","timestamp":1760617737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2013360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8,6]]}},"alternative-id":["BFbjc2013360"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2013.360","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]},"assertion":[{"value":"29 May 2013","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2013","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to\n                    Creative Commons licence terms, as noted at publication","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41416-025-03210-2","URL":"https:\/\/doi.org\/10.1038\/s41416-025-03210-2","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}